The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Intratumoral immunotherapy: using the tumor as the remedy
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 1×
“Accordingly, the loss of MHC expression has been related to secondary resistance to anti-PD-1 therapy [61, 62].”
BackgroundNivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611299 · Cited by 1,318
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M.-L., et al. (2010) · Nature · doi:10.1038/nature09460 · Cited by 1,317
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Dovedi, S. J., Adlard, A. L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J., Stratford, I. J., Poon, E., Morrow, M., Stewart, R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1258 · Cited by 1,313
Gerlinger, M., Horswell, S., Larkin, J., Rowan, A. J., Salm, M. P., Varela, I., Fisher, R., McGranahan, N., Matthews, N., Santos, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2891 · Cited by 1,208
Systemic effects of local radiotherapy
Formenti, S. C., & Demaria, S. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70082-8 · Cited by 1,021
COLEY, W. B. (1893) · The American Journal of the Medical Sciences · doi:10.1097/00000441-189305000-00001 · Cited by 995
Zeng, J., See, A. P., Phallen, J., Jackson, C. M., Belcaid, Z., Ruzevick, J., Durham, N., Meyer, C., Harris, T. J., Albesiano, E., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.12.025 · Cited by 889
Burnette, B. C., Liang, H., Lee, Y., Chlewicki, L., Khodarev, N. N., Weichselbaum, R. R., Fu, Y.-X., & Auh, S. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2820 · Cited by 878
Radiation-induced bystander signalling in cancer therapy
Prise, K. M., & O'Sullivan, J. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2603 · Cited by 810
Heo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3089 · Cited by 779
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711 · cited 1×
“Intratumoral oncolytic viruses have been shown to overcome resistance to anti-CTLA-4 therapy in preclinical models [48].”
BackgroundGolden, E. B., Demaria, S., Schiff, P. B., Chachoua, A., & Formenti, S. C. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0115 · Cited by 688
Antonia, S., Goldberg, S. B., Balmanoukian, A., Chaft, J. E., Sanborn, R. E., Gupta, A., Narwal, R., Steele, K., Gu, Y., Karakunnel, J. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00544-6 · Cited by 602 · cited 1×
“Moreover, combinations of anti-CTLA-4 with anti-PD-1/PD-L1 generate a much higher level of CTCAE grade 3–4 irAEs as opposed to anti-PD-1/PD-L1 or anti-CTLA-4 monotherapies [56, 57].”
BackgroundAscierto, P. A., Del Vecchio, M., Robert, C., Mackiewicz, A., Chiarion-Sileni, V., Arance, A., Lebbé, C., Bastholt, L., Hamid, O., Rutkowski, P., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30231-0 · Cited by 509
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., Kim, Y. H., Hoppe, R. T., Knox, S. J., Shin, L. K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9793 · Cited by 487
Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody
Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D., Melero, I., Hamid, O., Schmidt, H., Robert, C., Chiarion-Sileni, V., Ascierto, P. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1272 · Cited by 424
The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response
Stamell, E. F., Wolchok, J. D., Gnjatic, S., Lee, N. Y., & Brownell, I. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.03.017 · Cited by 387
Nauts, H. C., Swift, W. E., & Coley, B. L. (1946) · PubMed · Cited by 346
Schön, M. P., & Schön, M. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08265.x · Cited by 346
Jump-starting the immune system: prime–boosting comes of age
Woodland, D. L. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.11.009 · Cited by 346
Arits, A. H., Mosterd, K., Essers, B. A., Spoorenberg, E., Sommer, A., De Rooij, M. J., van Pelt, H. P., Quaedvlieg, P. J., Krekels, G. A., van Neer, P. A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70143-8 · Cited by 312
Andtbacka, R. H. I., Ross, M., Puzanov, I., Milhem, M., Collichio, F., Delman, K. A., Amatruda, T., Zager, J. S., Cranmer, L., Hsueh, E., et al. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5286-0 · Cited by 308
Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy
Russell, S. J., Federspiel, M. J., Peng, K.-W., Tong, C., Dingli, D., Morice, W. G., Lowe, V., O'Connor, M. K., Kyle, R. A., Leung, N., et al. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.04.003 · Cited by 274
A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy
Hiniker, S. M., Chen, D. S., Reddy, S., Chang, D. T., Jones, J. C., Mollick, J. A., Swetter, S. M., & Knox, S. J. (2012) · Translational Oncology · doi:10.1593/tlo.12280 · Cited by 247
Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally
Aznar, M. A., Tinari, N., Rullán, A. J., Sánchez-Paulete, A. R., Rodriguez-Ruiz, M. E., & Melero, I. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601145 · Cited by 230
Rook, A. H., Gelfand, J. M., Wysocka, M., Troxel, A. B., Benoit, B., Surber, C., Elenitsas, R., Buchanan, M. A., Leahy, D. S., Watanabe, R., et al. (2015) · Blood · doi:10.1182/blood-2015-02-630335 · Cited by 224
(2017) · doi:10.1158/2159-8290.cd-17-0256 · Cited by 223
TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG
Heldwein, K. A., Liang, M. D., Andresen, T. K., Thomas, K. E., Marty, A. M., Cuesta, N., Vogel, S. N., & Fenton, M. J. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0103026 · Cited by 221
Intratumoral Immunization: A New Paradigm for Cancer Therapy
Marabelle, A., Kohrt, H., Caux, C., & Levy, R. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2116 · Cited by 214
Self-citationKim, Y. H., Gratzinger, D., Harrison, C., Brody, J. D., Czerwinski, D. K., Ai, W. Z., Morales, A., Abdulla, F., Xing, L., Navi, D., et al. (2012) · Blood · doi:10.1182/blood-2011-05-355222 · Cited by 210
Carpentier, A., Metellus, P., Ursu, R., Zohar, S., Lafitte, F., Barrie, M., Meng, Y., Richard, M., Parizot, C., Laigle-Donadey, F., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop047 · Cited by 206
The storm has cleared: lessons from the CD28 superagonist TGN1412 trial
Hünig, T. (2012) · Nature Reviews Immunology · doi:10.1038/nri3192 · Cited by 194 · cited 1×
“agonistic antiCD28 or anti-CD137 mAbs) [58, 59].”
Pattern recognition receptors: immune targets to enhance cancer immunotherapy
Shekarian, T., Valsesia-Wittmann, S., Brody, J., Michallet, M. C., Depil, S., Caux, C., & Marabelle, A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx179 · Cited by 181
Self-citationBacillus C almette‐ G uérin immunotherapy for genitourinary cancer
Gandhi, N. M., Morales, Á., & Lamm, D. L. (2013) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11754.x · Cited by 150
Weide, B., Derhovanessian, E., Pflugfelder, A., Eigentler, T., Radny, P., Zelba, H., Pföhler, C., Pawelec, G., & Garbe, C. (2010) · Cancer · doi:10.1002/cncr.25156 · Cited by 148
Abscopal Effect in a Patient with Melanoma
Hiniker, S. M., Chen, D. S., & Knox, S. J. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1203984 · Cited by 143
Green, D. S., Bodman‐Smith, M. D., Dalgleish, A. G., et al. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07664.x · Cited by 128
(2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2165 · Cited by 127
Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.
Bolhuis, R. L. H., Lamers, C. H., Goey, S. H., Eggermont, A. M. M., Trimbos, J. B. M. Z., Stoter, G., Lanzavecchia, A., Re, E. D., Miotti, S., & Raspagliesi, F. (1992) · PubMed · Cited by 108
Regulatory T Cells in Radiotherapeutic Responses
Schaue, D., Xie, M. W., Ratikan, J. A., & McBride, W. H. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00090 · Cited by 102
Radiation induces an antitumour immune response to mouse melanoma
Perez, C. A., Fu, A., Onishko, H. M., Hallahan, D. E., & Geng, L. (2009) · International Journal of Radiation Biology · doi:10.3109/09553000903242099 · Cited by 89
A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma
Ray, A., Williams, M. A., Meek, S. M., Bowen, R. C., Grossmann, K. F., Andtbacka, R. H. I., Bowles, T. L., Hyngstrom, J. R., Leachman, S. A., Grossman, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10453 · Cited by 86
von Meyenn, F., Schaefer, M. H., Weighardt, H., Bauer, S., Kirschning, C. J., Wagner, H., & Sparwasser, T. D. (2006) · Immunobiology · doi:10.1016/j.imbio.2006.05.004 · Cited by 85
BCG immunotherapy for bladder cancer—the effects of substrain differences
Gan, C. M., Mostafid, H. A., Khan, M. S., & Lewis, D. J. (2013) · Nature Reviews Urology · doi:10.1038/nrurol.2013.194 · Cited by 82
Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody
Michot, J., Mazeron, R., Dercle, L., Ammari, S., Canova, C., Marabelle, A., Rose, S., Rubin, E. H., Deutsch, É., Soria, J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.017 · Cited by 63
Self-citationWang, E., Kang, D., Bae, K., Marshall, M. A., Pavlov, D., & Parivar, K. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.309 · Cited by 47
Radiotherapy and Toll-Like Receptor Agonists
Marabelle, A., Filatenkov, A., Sagiv-Barfi, I., & Kohrt, H. E. K. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.006 · Cited by 27
Self-citationGovindan, R. (2014) · Science · doi:10.1126/science.1259926 · Cited by 23
How should we use anti-CTLA-4 antibodies?
Marabelle, A., & Eggermont, A. M. M. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.002 · Cited by 8
Self-citation
Cited by
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Luchini, C., Bibeau, F., Ligtenberg, M. J. L., Singh, N., Nottegar, A., Bosse, T., Miller, R., Riaz, N., Douillard, J.-Y., Andre, F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz116 · Cited by 1,041
Harnessing innate immunity in cancer therapy
Demaria, O., Cornen, S., Daëron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019) · Nature · doi:10.1038/s41586-019-1593-5 · Cited by 957
Cancer nanomedicine for combination cancer immunotherapy
Nam, J., Son, S., Park, K. S., Zou, W., Shea, L. D., & Moon, J. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0108-1 · Cited by 940
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Korman, A. J., Garrett-Thomson, S. C., & Lonberg, N. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00345-8 · Cited by 548
Metadata
- Authors
- Marabelle, A., Tselikas, L., de Baere, T., & Houot, R.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 28
- Issue
- suppl_12
- Pages
- xii33-xii43
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2773106490
- Cited by
- 375
- References
- 58
- FWCI
- 8.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.